TNDM · CIK 0001438133
What Tandem Diabetes Care, Inc. told the SEC could break it.
Tandem's disclosures cluster on concentration at both ends of its insulin-pump business. On the way to market it sells largely through independent distributors — 63% of total U.S. sales in 2025 — with two distributors each accounting for more than 10% of worldwide sales, so losing or renegotiating either would materially cut sales until it can shift those volumes (it is beginning a move toward direct operations in 2026). On the supply side, it depends on a small number of component suppliers, some single-sourced and several located in China, Mexico, and Costa Rica, where medical-device qualification makes replacements slow — and that same international footprint exposes it to U.S. tariffs and trade-policy actions that could raise component costs it may be unable to fully pass through.
3 self-disclosed vulnerabilities, pulled from its own filings — each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Customer concentration
- Two unnamed independent distributors each >10% of worldwide sales; distributors = 63% of U.S. salesmedium
Tandem sells largely through independent distributors rather than direct: sales to distributors accounted for 63% of total U.S. sales in 2025, and for the year ended December 31, 2025 two independent distributors each accounted for more than 10% of worldwide sales. Loss of, or a contract change with, either >10% distributor — or a shift of patients to a single-source diabetes-supply distributor — would materially reduce sales until Tandem can transition those volumes (it is beginning a move toward direct operations in 2026). The distributors are unnamed, so this is a customer-concentration risk rather than a named edge.
“For the year ended December 31, 2025, two independent distributors each accounted for more than 10% of our worldwide sales.”
SEC filing →As of 2026
Regulatory & policy
- Tariff/trade-policy exposure on internationally sourced components (China, Mexico, Costa Rica) plus a Mexico third-party contract manufacturermedium
Tandem's hardware supply chain runs through tariff-sensitive geographies: it sources components from a limited number of suppliers in China, Mexico and Costa Rica and purchases certain inventory from a third-party contract manufacturer located in Mexico. It states that depending on a limited number of (partly international) suppliers exposes it to limited control over costs, including tariffs. New or increased U.S. tariffs (China Section 301, USMCA-region actions) on these imports would raise component/landed costs it may be unable to fully pass through. A quantified-geography trade-policy/tariff exposure on a hardware medical device.
“Depending on a limited number of suppliers exposes us to risks, including limited control over costs, including tariffs, availability, quality and delivery schedules.”
Supplier concentration
- Small number of component suppliers (some single-sourced) for an FDA-regulated device; medical-device qualification makes replacement slowmedium
Tandem depends on a small number of suppliers for the components and sub-assemblies of its insulin pumps, some single-sourced and some located internationally (China, Mexico, Costa Rica). Because medical-device manufacturing qualification is required, it may not be able to quickly establish additional or replacement sources; for sole-sourced parts it mitigates by holding inventory in-house and at the supplier. A supplier disruption, quality failure, or loss of a sole-source component vendor could halt pump production. Suppliers (other than Unomedical, captured as an edge) are unnamed, so this is a supplier-concentration/sole-source risk.
“We generally use a small number of suppliers for our components and products, some of which are located internationally, including in China, Mexico and Costa Rica.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings — including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its suppliers
Unomedical A/S (ConvaTec Group)
“infusion sets from a third-party supplier, Unomedical A/S, a subsidiary of the ConvaTec Group. Unomedical is responsible for all manufacturing, testing, sterilization and packaging of the infusion sets under our brands.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch